Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer

Abstract

Background: The immuno-modulatory effects of ionizing radiation are well-known and preclinical studies suggest a synergistic effect of combining radiotherapy (RT) and IO. However, data regarding the clinical activity and safety of this approach are limited.

Methods: We present the cases of two patients with SCCHN primary progressing to PDL1-based IO within a clinical trial (NCT03383094), that received subsequent but not concurrent palliative RT using two different modalities (electron beam and photon beam therapies).

Results: Both patients achieved major and durable responses at 4 irradiated sites, with excellent tolerance and no grade ≥ 3 toxicities. Complete response occurred in 3 of the disease areas (all locoregional) and partial response in 1 metastatic lesion.

Conclusion: Palliative radiotherapy after progression to IO was safe and demonstrated profound and durable responses in the cases presented.

Keywords: Durvalumab; Electron beam radiotherapy; Head and neck cancer; Immunotherapy; PDL1; Photon beam radiotherapy; Radiotherapy.